98%
921
2 minutes
20
Objectives: Stroke is a major cause of death and disability globally, especially among diabetic patients. In this study, we aim to scrutinise the effects of metformin on the clinical outcomes of stroke in diabetic patients.
Design: This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Data Sources: PubMed, Embase and Web of Science databases were searched between their inception and 5 December 2023.
Eligibility Criteria For Selecting Studies: Studies investigating the effect of metformin on the clinical outcomes of stroke in patients with diabetes were included.
Data Extraction And Synthesis: The effect of metformin on the clinical outcomes of stroke in patients with diabetes was identified using combined ORs and 95% CIs.
Results: A total of 11 studies involving 18 525 participants were included in this review. Pooled analysis has demonstrated that prestroke metformin use could reduce the probability of poor course after stroke by 34% in diabetes mellitus (DM) patients (OR=0.66, 95% CI: 0.61 to 0.72) and reduce the probability of death by 43% (OR=0.57, 95% CI: 0.51 to 0.64).
Conclusions: Prestroke metformin use is beneficial for the improvement of clinical outcomes in patients who had a stroke with DM, although the potential bias should be carefully considered.
Prospero Registration Number: CRD42024496056.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11751969 | PMC |
http://dx.doi.org/10.1136/bmjopen-2024-092214 | DOI Listing |
Pharmacotherapy
September 2025
Department of Biomedical Informatics, School of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Background: Omeprazole, a widely used proton pump inhibitor, has been associated with rare but serious adverse events such as myopathy. Previous research suggests that concurrent use of omeprazole with fluconazole, a potent cytochrome P450 (CYP) 2C19/3A4 inhibitor, may increase the risk of myopathy. However, the contribution of genetic polymorphisms in CYP enzymes remains unclear.
View Article and Find Full Text PDFJ Cereb Blood Flow Metab
September 2025
The Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating neurological disease, and one of the primary drivers of morbidity after aneurysm rupture is the phenomenon of delayed cerebral ischemia (DCI). Significant knowledge has been gained over the past two decades of the impact of neuroinflammation in DCI; and neutrophils are now believed to play a major role. There is significant human subject data showing the rise of neutrophil related inflammatory markers and neutrophil's association with poor outcome after aSAH, but as of yet no trials involving human subjects have been done specifically targeting neutrophils.
View Article and Find Full Text PDFHum Brain Mapp
September 2025
Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Perinatal stroke is a vascular injury occurring early in life, often resulting in motor deficits (hemiplegic cerebral palsy/HCP). Comorbidities may also include poor neuropsychological outcomes, such as deficits in memory. Previous studies have used resting state functional MRI (fMRI) to demonstrate that functional connectivity (FC) within hippocampal circuits is associated with memory function in typically developing controls (TDC) and in adults after stroke, but this is unexplored in perinatal stroke.
View Article and Find Full Text PDFMed J Aust
September 2025
Sydney School of Public Health, the University of Sydney, Sydney, NSW.
Objectives: To assess changes in greenhouse gas emission rates associated with the use of anaesthetic gases (desflurane, sevoflurane, and isoflurane) in Australian health care during 2002-2022, overall and by state or territory and hospital type.
Study Design: Retrospective descriptive analysis of IQVIA anaesthetic gases purchasing data.
Setting: All Australian public and private hospitals, 1 January 2002 - 31 December 2022.